Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide
Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide
Alzamend Neuro, Inc. (NASDAQ:ALZN) made waves Tuesday when the company announced its decision to terminate its "at-the-market" equity offering program. Shares were down nearly 12% at last check.
週二，Alzamend Neuro, Inc.（納斯達克股票代碼：ALZN）宣佈決定終止其 “市場” 股票發行計劃，引起了轟動。上次檢查時股價下跌了近12％。
What To Know: The move, aimed at minimizing uncertainty and preserving shareholder value, saw Alzamend cease further sales of common stock under its at-the-market equity offering, effectively concluding its obligations related to the program. Despite initiating the termination process ten days prior, the official cessation is scheduled for May 16, 2024.
須知：此舉旨在最大限度地減少不確定性並保持股東價值，使Alzamend停止了在市面股票發行下進一步出售普通股，實際上履行了與該計劃相關的義務。儘管在十天前啓動了終止程序，但正式停火定於2024年5月16日。
During the tenure of the offering program, Alzamend managed to sell approximately 1,076,821 shares of common stock, generating gross proceeds of around $1.3 million, translating to roughly $1.20 per share.
在發行計劃期間，Alzamend設法出售了約1,076,821股普通股，總收益約爲130萬美元，相當於每股約1.20美元。
Alzamend Neuro said its focus on advancing treatments for Alzheimer's, bipolar disorder, major depressive disorder and post-traumatic stress disorder remains unwavering. Anchored by innovative therapeutic candidates like AL001 and ALZN002, licensed from the University of South Florida Research Foundation, Alzamend said it plans to continue its mission to bring safe and effective treatments to market rapidly.
Alzamend Neuro表示，其對推進阿爾茨海默氏症、躁鬱症、重度抑鬱症和創傷後應激障礙治療的重點仍然堅定不移。Alzamend表示，在獲得南佛羅里達大學研究基金會許可的 AL001 和 ALZN002 等創新候選療法的支持下，它計劃繼續其使命，將安全有效的療法迅速推向市場。
The market reacted swiftly to the new developments, with Alzamend Neuro shares trading lower following the termination of the equity offering program. This strategic move underscores Alzamend's commitment to navigating challenges and maintaining shareholder confidence amid evolving market dynamics.
市場對新的事態發展迅速做出了反應，股票發行計劃終止後，Alzamend Neuro的股價走低。這一戰略舉措凸顯了Alzamend致力於在不斷變化的市場動態中應對挑戰和保持股東信心的承諾。
ALZN Price Action: Alzamend Neuro shares were down 11.9% at 62 cents Tuesday afternoon, according to Benzinga Pro.
ALZN價格走勢：根據Benzinga Pro的數據，週二下午Alzamend Neuro股價下跌11.9％，至62美分。
Image: courtesy of Alzamend Neuro.
圖片：由 Alzamend Neuro 提供。